MMW - Fortschritte der Medizin

, Volume 157, Issue 5, pp 45–50 | Cite as

Herzinsuffizienz mit erhaltener Ejektionsfraktion

Aktuelle und zukünftige Therapieansätze

FORTBILDUNG_SCHWERPUNKT
First Online:
  • 178 Downloads

Die „Herzinsuffizienz mit erhaltener Ejektionsfraktion (HFpEF)“, früher „diastolische Herzinsuffizienz“ genannt, kann bisher nur symptomatisch behandelt werden. Das sollte jedoch zu keinem therapeutischen Nihilismus führen, meint der Autor des nachfolgenden Beitrags. Welche Therapie ist empfehlenswert? Welche Ansätze befinden sich in der Entwicklung?

Heart failure with preserved ejection fraction (HFpEF)

Keywords - Heart failure with preserved ejection fraction (HFpEF)

Heart failure with preserved ejection management treatment LCZ 696 
This is a preview of subscription content, log in to check access.

Literatur

  1. 1.
    Farr, M.J., et al., Cardiopulmonary exercise variables in diastolic versus systolic heart failure. Am J Cardiol, 2008. 102(2): p. 203–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Lewis, E.F., et al., Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail, 2007. 9(1): p. 83–91.PubMedCrossRefGoogle Scholar
  3. 3.
    Lam CS, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. Eur J Heart Fail 2011; 13:18–28.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail 2012; 5:710–719.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    McMurray, J.J., et al., ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J, 2012. 33(14): p. 1787–847.PubMedCrossRefGoogle Scholar
  6. 6.
    Yancy CW, Jessup M, Bozkurt B, et al, American College of Cardiology Foundation, American Heart Association Task Force on Practice Guidlines. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;62(16):e147–239.PubMedCrossRefGoogle Scholar
  7. 7.
    Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012;59(11):998–1005.PubMedCrossRefGoogle Scholar
  8. 8.
    Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358(18):1887–98.PubMedCrossRefGoogle Scholar
  9. 9.
    ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major out-comes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981–97.CrossRefGoogle Scholar
  10. 10.
    James PA, Oparil S, Carter BL, et al. 2014 evidencebased guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014;311(5):507–20.PubMedCrossRefGoogle Scholar
  11. 11.
    Senni M, Paulus WJ, Gavazzi A, Fraser AG, Díez J, Solomon SD, Smiseth OA, Guazzi M, Lam CS, Maggioni AP, Tschöpe C, Metra M, Hummel SL, Edelmann F, Ambrosio G, Stewart Coats AJ, Filippatos GS, Gheorghiade M, Anker SD, Levy D, Pfeffer MA, Stough WG, Pieske BM. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J. 2014 Oct 21;35(40):2797–815.).PubMedCrossRefGoogle Scholar
  12. 12.
    Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994;23(6):1410–20.PubMedCrossRefGoogle Scholar
  13. 13.
    Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994;23(6):1410–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008;359(23):2456–67.PubMedCrossRefGoogle Scholar
  15. 15.
    Yamamoto, K., et al., Effects of carvedilol on heart failure with preserved ejection fraction: the Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail, 2013. 15(1): p. 110–8.PubMedCrossRefGoogle Scholar
  16. 16.
    an Veldhuisen, D.J., et al., Beta-Blockade With Nebivolol in Elderly Heart Failure Patients With Impaired and Preserved Left Ventricular Ejection Fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). Journal of the American College of Cardiology, 2009. 53(23): p. 2150–2158.CrossRefGoogle Scholar
  17. 17.
    Hernandez AF, Hammill BG, O’Connor CM, et al. Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. J Am Coll Cardiol 2009;53(2):184–92.PubMedCentralPubMedCrossRefGoogle Scholar
  18. 18.
    Massie BM, Nelson JJ, Lukas MA, et al. Comparison of outcomes and usefulness of car-vedilol across a spectrum of left ventricular ejection fractions in patients with heart failure in clinical practice. Am J Cardiol 2007;99(9):1263–8.PubMedCrossRefGoogle Scholar
  19. 19.
    Lund L, Benson L, Dahlström U, Edner M, Friberg L. Association between use of β-blockers and outcomes in patients with heart failure and preserved ejection fraction. JAMA. 2014 Nov 19;312(19):2008–18.PubMedCrossRefGoogle Scholar
  20. 20.
    Edelmann F, Wachter R, Schmidt AG, et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHFrandomized controlled trial. JAMA 2013;309(8):781–91.PubMedCrossRefGoogle Scholar
  21. 21.
    Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 2014;370(15):1383–92.PubMedCrossRefGoogle Scholar
  22. 22.
    Setaro JF, Zaret BL, Schulman DS, et al. Usefulness of verapamil for congestive heart failure associated with abnormal left ventricular diastolic filling and normal left ventricular sys-tolic performance. Am J Cardiol 1990;66(12):981–6.PubMedCrossRefGoogle Scholar
  23. 23.
    Maier L.S, Layug B, Karwatowska-Prokopczuk E, Belardinelli L, Lee S, Sander J, et al. Ranolazine for the treatment of diastolic heart failure in patients with preserved B ejection fraction: the RALI-DHF proof-of-concept study. JACC Heart Fail 2013: 1, 115–122.PubMedCrossRefGoogle Scholar
  24. 24.
    Becher PM, Lindner D, Miteva K, Savvatis K, Zietsch C, Schmack B, Van Linthout S, Westermann D, Schultheiss HP, Tschöpe C. Role of heart rate reduction in the prevention of experimental heart failure: comparison between If-channel blockade and β-receptor blockade. Hypertension. 2012 May;59(5):949–57.PubMedCrossRefGoogle Scholar
  25. 25.
    Kosmala W, Holland DJ, Rojek A, Wright L, Przewlocka-Kosmala M, Marwick TH. Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 2013;62:1330–1338PubMedCrossRefGoogle Scholar
  26. 26.
    Solomon SD, Zile M, Pieske B, et al. Prospective comparison of AwARBoMOhfwpefI. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: a phase 2 doubleblind randomised controlled trial. Lancet 2012; 380(9851):1387–95.PubMedCrossRefGoogle Scholar
  27. 27.
    Pieske B, Butler J, Filippatos G, Lam C, Maggioni AP, Ponikowski P, Shah S, Solomon S, Kraigher-Krainer E, Samano ET, Scalise AV, Müller K, Roessig L, Gheorghiade M; SOCRATES Investigators and Coordinators. Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES). Eur J Heart Fail. 2014 Sep;16(9):1026–38.PubMedCrossRefGoogle Scholar
  28. 28.
    Kasner M, Westermann D, Steendijk P, Dröse S, Poller W, Schultheiss HP, Tschöpe C. Left ventricular dysfunction induced by nonsevere idiopathic pulmonary arterial hypertension: a pressure-volume relationship study. Am J Respir Crit Care Med. 2012 Jul 15;186(2):181–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Redfield MM, Chen HH, Borlaug BA, et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a ran-domized clinical trial. JAMA 2013;309(12):126859. CrossRefGoogle Scholar
  30. 30.
    Zile MR, Bourge RC, Redfield MM, Zhou D, Baicu CF, Little WC. Randomized, double-blind, placebo-controlled study of sitaxsentan to improve impaired exercise tolerance in patients with heart failure and a preserved ejection fraction. CC Heart Fail. 2014 Apr;2(2):123–30.Google Scholar
  31. 31.
    Van Tassell BW, Arena R, Biondi-Zoccai G, McNair Canada J, Oddi C, Abouzaki NA, Jahangiri A, Falcao RA, Kontos MC, Shah KB, Voelkel NF, Dinarello CA, Abbate A. Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and reserved ejection fraction (from the D-HART pilot study). Am J Cardiol. 2014 Jan 15;113(2):321–7PubMedCrossRefGoogle Scholar
  32. 32.
    Sacherer M, Sedej S, Wakuła P, Wallner M, Vos MA, Kockskämper J, Stiegler P, Sereinigg M, von Lewinski D, Antoons G, Pieske BM, Heinzel FR; CONTICA investigators. JTV519 (K201) reduces sarcoplasmic reticulum Ca2+ leak and improves diastolic function in vitro in murine and human non-failing myocardium. Br J Pharmacol. 2012 Oct;167(3):493–504PubMedCentralPubMedCrossRefGoogle Scholar
  33. 33.
    Kamimura D, Ohtani T, Sakata Y, Mano T, Takeda Y, Tamaki S, et al. Ca2+ entry mode of Na+/Ca2+exchanger as a new therapeutic target for heart failure with preserved ejection fraction. Eur Heart J 2012: 33, 1408–1416PubMedCrossRefGoogle Scholar
  34. 34.
    Edelmann F, Gelbrich G, Dungen HD, et al. Exercise training improves exercise capacity and diastolic function in patients with heart failure with preserved ejection fraction: results of the Ex-DHF (Exercise training in Diastolic Heart Failure) pilot study. J Am Coll Cardiol 2011;58(17):1780–91PubMedCrossRefGoogle Scholar
  35. 35.
    Zile MR, Bennett TD, St John Sutton M, Cho YK, Adamson PB, Aaron MF, et al. Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures. Circulation 2008;118(14):1433–41PubMedCrossRefGoogle Scholar
  36. 36.
    Sinning D, Kasner M, Westermann D, Schulze K, Schultheiss HP, Tschöpe C. Increased left ventricular stiffness impairs exercise capacity in patients with heart failure symptoms despite normal left ventricular ejection fraction. Cardiol Res Pract. 2011 Mar 2;2011: 692862.PubMedCentralPubMedGoogle Scholar
  37. 37.
    Søndergaard L, Reddy V, Kaye D, Malek F, Walton A, Mates M, Franzen O, Neuzil P, Ihlemann N, Gustafsson F. Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure. Eur J Heart Fail. 2014 Jul;16(7):796–801PubMedCrossRefGoogle Scholar
  38. 38.
    Kasner M, Westermann D, Schultheiss HP, Tschöpe C. Diastolic heart failure and LV dyssynchrony. Curr Pharm Biotechnol. 2012 Oct;13(13):2539–44PubMedCrossRefGoogle Scholar
  39. 39.
    Menet A, Greffe L, Ennezat PV, Delelis F, Guyomar Y, Castel AL, Guiot A, Graux P, Tribouilloy C, Marechaux S. Is mechanical dyssynchrony a therapeutic target in heart failure with preserved ejection fraction? Am Heart J. 2014 Dec;168(6):909–916PubMedCrossRefGoogle Scholar
  40. 40.
    Borggrefe M, Burkhoff D. Clinical effects of cardiac contractility modulation (CCM) as a treatment for chronic heart failure. Eur J Heart Fail. 2012 Jul;14(7):703–12PubMedCrossRefGoogle Scholar
  41. 41.
    Van Heerebeek L, Hamdani N, Falcão-Pires I, Leite-Moreira AF, Begieneman MP, Bronzwaer JG, van der Velden J, Stienen GJ, Laarman GJ, Somsen A, Verheugt FW, Niessen HW, Paulus WJ. Low myocardial protein kinase G activity in heart failure with preserved ejection fraction. Circulation. 2012 Aug 14;126(7):830–9PubMedCrossRefGoogle Scholar

Copyright information

© Urban & Vogel 2015

Authors and Affiliations

  1. 1.Charité, Campus Rudolf VirchowBerlinDeutschland

Personalised recommendations